Global Antisense & RNAi Therapeutics Market
The global antisense & RNAi therapeutics market is estimated to be worth over USD 22.69 Bn in 2033 and is expected to grow at CAGR of 18.6% during the forecast period (2024-2033). The global antisense & RNAi therapeutics market, in these times, is witnessing a swift and revolutionary emergence, driven by leading-edge research, advanced developments, and a broadeningarray of applications. The growing focus on personalized medicines and the customized treatment of various ailments is one of the primary factors that is driving the antisense & RNAi therapeutics market growth.
In the past few years, this market has witnessednotableadvances in the delivery of oligonucleotide-based therapies. Groundbreaking delivery mechanisms, including lipid nanoparticles and conjugates, are revolutionizing the efficacy of drug transport. Remarkably, Moderna's lipid nanoparticle technology, strikinglyexhibited in their successful COVID-19 vaccine, has not only propelled the cobat against the pandemic but also created a standard for more personalized and efficaciousoffering of RNA-based therapeutics.
The ever-growing applications of antisense and RNAi technologies are another trademark of the market's swifttransformation. Beyond their earlyachievements in rare genetic disorders, these therapies are opening up new horizons in addressing complex, prevalent ailments. Alzheimer's disease, a dauntinggainsay in healthcare, is experiencinggroundbreakingadvancements and innovations. Biogen's Aduhelm, an antisense therapy targeting amyloid-beta, is a fresh instance. Its FDA approval marked a notable step toward addressing Alzheimer's disease, providing promise to patients across the world.
Furthermore, the market's focus on neurological disorders is intensifying. Amyotrophic lateral sclerosis (ALS), a debilitating condition with limited treatment options, is now in the spotlight. New research and clinical trials exploring RNAi therapies for ALS hold the potential to change the landscape of care for these patients, bringing the market closer to innovative and personalized solutions.
Along with that, regulatory authorities are holding a crucial role in the swiftadvent of this market. They are determining the potential of antisense and RNAi therapies, speeding up approvals for these notable treatments. This recognition from regulatory agenciesmirrors the urgency to address previously underserved medical needs and highlights the revolutionaryinfluence these therapies can have on patients' lives.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:
A preface providing an introduction to the full report, antisense & RNAi therapeutics market, 2023-2033.
An outline of the systematic research methodology adopted to conduct the study on Antisense & RNAi Therapeutics market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
An overview of economic factors that impact the overall antisense & RNAi therapeutics market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
An executive summary of the insights captured during our research, offering a high-level view of the current state of the antisense & RNAi therapeutics market and its likely evolution in the mid-to-long term.
A brief introduction to the antisense & RNAi therapeutics, highlighting their historical background, as well as information on their types, key aspects, key challenges and the advantages of using antisense & RNAi therapeutics.
A detailed assessment of the market landscape of antisense & RNAi therapeutics that are either approved or being evaluated in different stages of development, based on several relevant parameters, such as by technology (RNA Interference, Antisense RNA), application (Genetic Disease, Cancer, Infectious Disease, Neurodegenerative Disorders, Cardio Metabolic & Renal Disorders, Ocular Disorders, Respiratory Disorders, Skin Disorders, Others), route of administration (Intravenous Injections, Intrathecal Injections, Subcutaneous Injections, Other Delivery Methods). Further, the chapter features analysis on key niche market segments. In addition, the chapter features analysis of various antisense & RNAi therapeutics developers, based on their year of establishment, company size, location of headquarters and most active players.
An in-depth analysis of partnerships and collaborations that have been inked between various stakeholders, since 2019, based on several relevant parameters, such as the year of partnership, type of partnership, focus of partnership, purpose of partnership, therapeutic applications and most active players (in terms of number of partnerships). It also highlights the regional distribution of partnership activity in this market.
A detailed analysis of various investments made by companies engaged in this industry, since 2019, based on several relevant parameters, such as year of funding, type of funding (grants, seed, venture capital, initial public offering, secondary offerings, private equity and debt financing), type of HPAPIs, amount invested, geography, purpose of funding, stage of development, therapeutic area, most active players (in terms of number and amount of funding instances) and leading investors (in terms of number of funding instances).
An in-depth analysis of the various antisense & RNAi therapeutics focused initiatives undertaken by big market players, based on several relevant parameters, such as number of initiatives, year of initiative, type of initiative, purpose of initiative, focus of initiative and location of headquarters of the big pharma players.
One of the key objectives of this market report was to estimate the current market size and the future growth potential of the antisense & RNAi therapeutics over the forecast period. Based on several parameters, such as regional analysis as well as segmental analysis rates, we have developed informed estimates of the likely evolution of the antisense & RNAi therapeutics market over the forecast period 2023-2033. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as technology (RNA Interference, Antisense RNA), application (Genetic Disease, Cancer, Infectious Disease, Neurodegenerative Disorders, Cardio Metabolic & Renal Disorders, Ocular Disorders, Respiratory Disorders, Skin Disorders, Others), route of administration (Intravenous Injections, Intrathecal Injections, Subcutaneous Injections, Other Delivery Methods), key geographical regions (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) and leading players. In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.